- Exact Sciences (EXAS, Financial) unveils expanded validation of its Oncodetect™ MRD test for colorectal cancer at ASCO 2025.
- The next-generation Oncodetect test, leveraging MAESTRO technology, is set for a 2026 launch.
- Study results show a significant enhancement in predicting cancer recurrence compared to standard care.
Exact Sciences Corp. (EXAS), a leader in cancer diagnostics, has announced significant findings from the Beta-CORRECT clinical validation study for its molecular residual disease (MRD) test, Oncodetect™, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study reinforces the test’s efficacy in predicting recurrence in stage II–IV colorectal cancer, supporting treatment and surveillance decisions.
The company plans to introduce a next-generation version of the Oncodetect test in 2026, utilizing the Broad Institute’s MAESTRO technology. This advancement will enable the test to monitor up to 5,000 patient-specific variants and detect ctDNA levels below 1 part per million. The innovation aims to increase the test's sensitivity and broaden its clinical utility.
Results from the Beta-CORRECT study highlight that patients with ctDNA-positive results post-therapy demonstrate a significantly higher risk of recurrence, by 24 and 37 times, during surveillance periods. By quantifying ctDNA across multiple time points, Oncodetect aids physicians in making more informed treatment and surveillance decisions.
Exact Sciences maintains exclusive rights to the MAESTRO technology, which enhances the ability to detect low-frequency ctDNA mutations with high accuracy, promising cost-effective and scalable monitoring solutions. Viktor Adalsteinsson, Ph.D., from the Broad Institute, emphasized that these developments mark a significant step forward in recurrence monitoring and patient outcomes.
